$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Medical drugs
Medical drugs
Medical drugs-Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Baricitinib shows better efficacy than traditional hair loss treatment
2026-02-01 22:25:32
Check Details
Combination of tucatinib and apelvis shows efficacy in patients with HER2-positive metastatic breast cancer
2026-02-01 22:25:32
Check Details
Summary of clinical trial data of Apelvis-Piqray in the field of lung cancer
2026-02-01 22:25:32
Check Details
Has fotantinib/fotantinib been successfully copied in India?
2026-02-01 22:25:32
Check Details
What important information is included in the labeling for lenvatinib/lenvatinib
2026-02-01 22:25:32
Check Details
Boxed warning added to labels for treatment of conditions in postmenopausal women with fezonatant
2026-02-01 22:25:32
Check Details
Will Besudil Mesylate Tablets be included in medical insurance in 2025?
2026-02-01 22:25:32
Check Details
Purchasing channels for Brivaracetam/Brivaracetam after they are launched in the country
2026-02-01 22:25:32
Check Details
The main functions and therapeutic effects of obeticholic acid tablets
2026-02-01 22:25:32
Check Details
What is the difference in efficacy between neratinib/neratinib and pyrotinib?
2026-02-01 22:25:32
Check Details
How to apply for bedaquiline to treat drug-resistant tuberculosis
2026-02-01 22:25:32
Check Details
What specifications should be followed when taking dasatinib?
2026-02-01 22:25:32
Check Details
1
2
...
1566
1567
1568
1569
1570
1571
1572
...
2441
2442
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Bepirovirsen for Chronic HBV Functional Cure: FDA Criteria and B-Well Data
2
Hovilpri (Pritelivir) Oral Anti-HSV: Immunocompromised Adults With Acyclovir-Refractory Mucocutaneous Lesions, 63% Healing at 28 Days
3
Juvmo (tavapadon) for Adult Parkinson’s: D1/D5 Partial Agonist, Once Daily, Monotherapy or Adjunct to Levodopa
4
Emcitate (tiratricol) for MCT8 Deficiency Peripheral Thyrotoxicosis: Bypass MCT8, Lower T3, Monitor Heart Rate and Bone
5
Lyrfigtu (lirafugratinib) for Pretreated FGFR2 Cholangiocarcinoma: 70mg Daily, REFOCUS Efficacy, Ocular and Phosphate Monitoring
6
Fayuvi (rebisufligene etisparvovec-hopf/UX111) for MPS IIIA: AAV9 SGSH Gene Therapy, Cognition, and Safety
7
Ramosetron Hydrochloride Orally Disintegrating Tablets: A 5-HT3 Receptor Antagonist for Diarrhea-Predominant IBS
8
Pixclara (Floretyrosine F-18/18F-FET) Glioma PET: Distinguishing Recurrence from Treatment-Related Change
9
Bexlutry (Lu-177 Dotatate) for SSTR-Positive GEP-NETs: PRRT Dosing and Safety Monitoring
10
Hibsago (Bepirovirsen) Japan Approval: CHB Functional Cure and B-Well Data Essentials
11
FDA Approves Isembyld (apitegromab-mstn), the World’s First Skeletal Muscle-Targeted Therapy for SMA
12
Mirogabalin for Neuropathic Pain: Onset Time and Dosing Strategy